Cladribine Dose Escalation in Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) for Refractory Acute Leukemia and Myelodysplastic Syndromes

2024-515737-14-00 Protocol CEREAL-IPC 2016-010 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 7 Oct 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol CEREAL-IPC 2016-010

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 29
Countries 1
Sites 1

Acute leukemia and myelodysplastic syndromes

Key facts

Sponsor
Institut Paoli Calmettes
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20], Diseases [C] - Neoplasms [C04]
Trial duration
7 Oct 2024 → ongoing
Decision date (initial)
2024-10-07
Transition trial
Yes
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

External identifiers

EU CT number
2024-515737-14-00
EudraCT number
2016-004127-23
WHO UTN
U1111-1310-3269
ClinicalTrials.gov
NCT03235973

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Acute leukemia and myelodysplastic syndromes

VersionLevelCodeTermSystem organ class
27.0 PT 10028533 Myelodysplastic syndrome 100000004864
21.0 LLT 10000835 Acute leukemia 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut Paoli Calmettes

Sponsor organisation
Institut Paoli Calmettes
Address
232 Boulevard De Sainte Marguerite, Bp 156 Bp 156
City
Marseille
Postcode
13009
Country
France

Scientific contact point

Organisation
Institut Paoli Calmettes
Contact name
Dr Raynier DEVILLIER

Public contact point

Organisation
Institut Paoli Calmettes
Contact name
Marina LAROSA

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 29 1
Rest of world 0

Investigational sites

France

1 site · Ongoing, recruiting
Institut Paoli Calmettes
Oncologie médicale, 232 Boulevard De Sainte Marguerite, Bp 156, Marseille

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-10-07 2024-10-07

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-23 France Acceptable
2024-10-07
2024-10-07
2 SUBSTANTIAL MODIFICATION SM-1 2026-03-11 France Acceptable
2026-04-03
2026-05-21